Virtu Financial’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-24,661
| Closed | -$531K | – | 1631 |
|
|
2025
Q4 | $531K | Buy |
+24,661
| New | +$479K | 0.02% | 574 |
|
|
2023
Q4 | – | Sell |
-20,047
| Closed | -$206K | – | 1559 |
|
|
2023
Q3 | $206K | Buy |
+20,047
| New | +$268K | 0.02% | 650 |
|
|
2023
Q2 | – | Sell |
-16,759
| Closed | -$154K | – | 1507 |
|
|
2023
Q1 | $154K | Buy |
16,759
+1,449
| +9% | +$11.9K | 0.02% | 827 |
|
|
2022
Q4 | $110K | Buy |
15,310
+4,769
| +45% | +$33.4K | 0.01% | 922 |
|
|
2022
Q3 | $53K | Buy |
+10,541
| New | +$58K | ﹤0.01% | 1188 |
|
|
2022
Q1 | – | Sell |
-25,427
| Closed | -$205K | – | 1487 |
|
|
2021
Q4 | $205K | Buy |
+25,427
| New | +$232K | 0.02% | 827 |
|
|
2021
Q1 | – | Sell |
-14,461
| Closed | -$97K | – | 1587 |
|
|
2020
Q4 | $97K | Buy |
+14,461
| New | +$90.4K | 0.01% | 1060 |
|
|
2020
Q3 | – | Sell |
-33,048
| Closed | -$267K | – | 1044 |
|
|
2020
Q2 | $267K | Buy |
+33,048
| New | +$291K | 0.03% | 601 |
|
|
2018
Q1 | – | Sell |
-12,959
| Closed | -$106K | – | 1938 |
|
|
2017
Q4 | $106K | Sell |
12,959
-249
| -2% | -$2.33K | 0.01% | 1901 |
|
|
2017
Q3 | $139K | Buy |
+13,208
| New | +$126K | 0.01% | 1985 |
|
Other funds holding AVDL
Virtu Financial's AVDL Position: Q1 2026 in Review
Virtu Financial sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 24,661 shares — an estimated $531K sold.
Virtu Financial first reported a position in AVDL in Q3 2017 and held it in 10 quarters. The position peaked at $531K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- Virtu Financial reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Virtu Financial sold 24,661 Avadel Pharmaceuticals shares in Q1 2026, an estimated $531K.
- Virtu Financial first reported a position in Avadel Pharmaceuticals in Q3 2017 and held it in 10 quarters.
- Virtu Financial's Avadel Pharmaceuticals position peaked at $531K in Q4 2025.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.